UNC0 Stock Chart & Stats
€121.00
€0.00(0.00%)
At close: 4:00 PM EDT
€121.00
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€90.50 - €142.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€47.54B
Enterprise Value€54.14K
Total Cash (Recent Filing)€2.47B
Total Debt (Recent Filing)€2.24B
Price to Earnings (P/E)30.5
Beta0.58
Next Earnings
Jul 30, 2026EPS Estimate
3.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.08
Shares Outstanding389,011,320
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.76
Price to Book (P/B)4.16
Price to Sales (P/S)6.08
P/FCF Ratio25.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)5.46
Revenue Forecast (FY)€8.60B
Bulls Say, Bears Say
Bulls Say
Cash GenerationMaterial free cash flow improvement in 2025 reflects stronger cash earnings quality and provides durable funding for R&D, capex and strategic investments. Sustained cash conversion supports deleveraging, optionality for partnerships and resilience through clinical or pricing cycles.
Diversified Growth DriversA multi-franchise growth base with BIMZELX scale and five drivers doubling contribution lessens reliance on any single asset. Geographic expansion and high patient uptake create structural revenue tailwinds, increasing probability revenues remain elevated over coming years.
Balance Sheet ImprovementNotable debt reduction and a meaningful equity base improve financial flexibility and lower leverage risk. Stronger balance sheet underpins large strategic commitments (e.g., manufacturing build) and reduces refinancing/interest exposure, supporting longer-term investment capacity.
Bears Say
Margin PressureOperating profit decline despite top-line growth signals rising operating costs (R&D and M&S) or mix shifts. Persistent margin compression would constrain sustainable net income and free cash flow expansion, requiring continued discipline to preserve profitability gains.
Net Price / Gross‑to‑net RiskGrowing rebates and access-driven gross‑to‑net adjustments are structural for biologics as U.S. coverage expands. Even with volume growth, lower net realizations can materially blunt revenue and margin upside over time unless offset by price or mix improvements.
Loss Of Exclusivity (LOE) ExposureLOE for established products creates predictable revenue erosion for mature franchises. Sustainable growth depends on timely commercialization and scaling of pipeline assets; failure or delays would increase pressure to replace lost sales and justify R&D spend.
UCB SA News
UNC0 FAQ
What was UCB SA’s price range in the past 12 months?
UCB SA lowest stock price was €90.50 and its highest was €142.00 in the past 12 months.
What is UCB SA’s market cap?
UCB SA’s market cap is €47.54B.
When is UCB SA’s upcoming earnings report date?
UCB SA’s upcoming earnings report date is Jul 30, 2026 which is today.
How were UCB SA’s earnings last quarter?
Currently, no data Available
Is UCB SA overvalued?
According to Wall Street analysts UCB SA’s price is currently Overvalued.
Does UCB SA pay dividends?
UCB SA does not currently pay dividends.
What is UCB SA’s EPS estimate?
UCB SA’s EPS estimate is 3.26.
How many shares outstanding does UCB SA have?
UCB SA has 389,011,320 shares outstanding.
What happened to UCB SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of UCB SA?
Currently, no hedge funds are holding shares in DE:UNC0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
UCB SA Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.10%
12-Months-Change
Fundamentals
Return on Equity
0.58%
Trailing 12-Months
Asset Growth
18.72%
Trailing 12-Months
Company Description
UCB SA
UCB S.A. is a biopharmaceutical enterprise dedicated to developing innovative treatments and solutions for individuals living with neurological and immunological diseases. Its primary product, Cimzia, addresses a spectrum of inflammatory TNF-mediated conditions, encompassing ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. For epilepsy management, the company provides Vimpat, Keppra, and Briviact, alongside Nayzilam, an emergency nasal spray for seizure clusters. Neupro is offered for Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal alleviate allergy symptoms. The portfolio further extends to Evenity, a treatment for osteoporosis in postmenopausal women, and BIMZELX, used for psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. Dapirolizumab pegol is also available for systemic lupus erythematosus. UCB maintains a robust development pipeline featuring therapies such as rozanolixizumab for myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for stereotypic prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Additionally, the company engages in contract manufacturing services. UCB S.A. has forged collaborative agreements with partners including Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. Its operational presence spans the United States, Japan, Germany, a broader European footprint (including Spain, France, Italy, the United Kingdom, and Ireland), China, Belgium, and other global territories. Incorporated in 1925, the company's headquarters are situated in Brussels, Belgium.